Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 17, 2023
Reporting Period: Single event date (August 17, 2023)
This filing announces the company's participation in the 2023 Sidoti Micro-Cap Virtual Conference. The presentation, titled "Next Generation Chemotherapy: Improved Treatment for More Patients," was delivered by David Young, Pharm.D., Ph.D., President of Research and Development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding a corporate event and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely discloses the occurrence of a scheduled investor presentation.
Guidance, Outlook, and Risks
- Management Commentary: The company presented on its next-generation chemotherapy pipeline. The full presentation is available as Exhibit 99.1 and on the company's investor website.
- Forward-Looking Statements: Processa explicitly states it undertakes no duty or obligation to publicly update or revise the information contained in this report, though it may do so through future filings or press releases.
- Regulatory Disclosure: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the content of the presentation (Exhibit 99.1) regarding the "Next Generation Chemotherapy" pipeline.
- Check the "Investors" section of the company website for the archived presentation.
- Review subsequent filings for any updates or revisions to the information presented on August 17, 2023.